Autolus Therapeutics plc (AUTL) stock
AUTLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/3019% below fair value
$1.14−0.03 (-2.56%)
Close on Nov 16, 2026Market cap $303.43MP/E –Yield –
Autolus Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Autolus Therapeutics's enterprise value was $127.06M on Nov 11, 2026, against $7.86M a year earlier. Over the last 5 years it ranged from -$229.67M to $869.41M, with a median of $20.93M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $127.06M | -21.7% |
| 2025 | Dec 31, 2025 | $162.23M | – |
| 2024 | Dec 31, 2024 | -$111.65M | -114.8% |
| 2023 | Dec 29, 2023 | $755.56M | – |
| 2022 | Dec 30, 2022 | -$26.09M | -158.1% |
| 2021 | Dec 31, 2021 | $44.88M | -57.0% |
| 2020 | Dec 31, 2020 | $104.42M | -38.6% |
| 2019 | Dec 31, 2019 | $169.95M | -78.5% |
| 2018 | Dec 31, 2018 | $789.73M | – |
See a number that looks wrong?